Cascina Perseghetto

This research aims to compare progression-free survival in adults with metastatic colorectal cancer harboring the KRAS p.G12C mutation who have not yet received treatment. The study evaluates the effectiveness of combining sotorasib, panitumumab, and FOLFIRI chemotherapy versus FOLFIRI chemotherapy with or without bevacizumab-awwb. This comparison is important for understanding treatment options for this specific cancer mutation. Participants will be randomly assigned to one of two treatment groups. One group will take sotorasib orally every day along with panitumumab and FOLFIRI given by intravenous infusion every two weeks. The other group will receive FOLFIRI chemotherapy every two weeks, with or without bevacizumab-awwb infusion. Treatments will continue as per study protocol to assess their impact on cancer progression. During the study, participants will have their disease monitored using imaging tests based on RECIST v1.1 criteria for up to about three years to measure progression-free survival. Additional outcomes such as overall survival, response rates, duration of response, and adverse events will be tracked for up to five years. The study includes regular medical assessments, laboratory tests, and safety monitoring throughout the treatment and follow-up periods.

Researchers are evaluating the real-life effectiveness and safety of three different treatmentsvedolizumab, ustekinumab, and JAK inhibitorsin patients with ulcerative colitis UC who have previously been treated with at least one anti-TNF-alpha therapy. This observational study aims to compare these therapies over a period of 12 months to better understand how they perform in routine clinical settings. The study includes patients who are starting one of the three treatments as a second-line target therapy after anti-TNF-alpha failure or intolerance. The treatments being observed are vedolizumab, ustekinumab at standard dosage, and JAK inhibitors such as tofacitinib, upadacitinib, or filgotinib. Participants receive their prescribed treatments as part of their usual medical care the study monitors their progress and outcomes without altering treatment. Participants will be followed for at least one visit after starting the treatment to assess clinical and endoscopic effectiveness over 12 months. Researchers will collect data on how well each treatment controls disease activity and safety profiles. The study involves regular clinical assessments according to routine practice to evaluate participants health status and treatment responses during this period.